Kornimate/medical-research-clean huggingface dataset:
platelet-rich fibrin and grooving for sagittal split osteotomy

Conditions: Inferior Alveolar Nerve Injury; Nerve Injury; Neurosensory Disorder; Mandibular Nerve Injury

Summary: sagittal split osteotomy (sso) is a common operation done to move the mandible to correct dentofacial deformities and obstructive sleep apnea (osa). inferior alveolar nerve (ian) injury and associated paresthesia is a well-known negative outcome following sso, causing temporary or sometimes, permanent numbness in the chin and/or lip. there are limited methods to decrease the occurrence and duration of neurosensory dysfunction. recent research has shown that platelet-rich fibrin (prf) aids neurosensory recovery after sso. another method to minimize nerve injury is proximal segment grooving (psg) to create space for the nerve to rest. this grooving method has never been formerly reported. the purpose of this study is to answer the following question: among patients undergoing bilateral sagittal split osteotomy (bsso) for dentofacial deformity or osa, do those who receive prf with or without psg, compared to those who do not, have shorter times to functional sensory recovery (fsr) of the ian? the null hypothesis is that there is no difference among 4 treatment groups and neurosensory outcomes. the specific aims of this proposal are to 1) enroll and randomize subjects who will undergo bsso for correction of dentofacial deformity or osa into 4 different treatment groups (psg with prf, psg alone, prf alone, neither psg or prf), 2) measure objective and subjective post-operative nerve function at fixed intervals post-operatively for up to 1 year, 3) compare differences in neurosensory outcomes among treatment groups, and 4) identify other variables that might be associated with differences in neurosensory outcomes.


Eligibility criteria:
inclusion criteria: inclusion criteria include patients ages 18 and older, male or female, with a diagnosis of dentofacial deformity and/or osa who will undergo bsso. exclusion criteria: exclusion criteria include patients with a history of previous mandibular surgery and preoperative neurosensory dysfunction of the trigeminal nerve. other exclusion criteria are patients without capacity to consent for themselves or unable to read the consent form. subjects who have conditions which may impair healing (such those on bisphosphonates treatments, blood thinners, corticosteroids, chemotherapy, etc.) will be excluded from participation in the research.
temsirolimus (torisel) drug use investigation (regulatory post marketing commitment plan)

Conditions: Renal Cell Carcinoma

Summary: the objective of this investigation is to determine the following items in all patients receiving torisel for a certain period after marketing: 1. confirmation of efficacy and safety for medical practice use. 2. investigation of factors that may influence the incidence of adverse events (particularly priority investigation items). 3. investigation of the incidence status and the risk factors for interstitial lung diseases.

implemented as a drug use investigation by central registration system

Eligibility criteria:
inclusion criteria: * patients treated with torisel (patients with metastatic and/or radically unresectable or advanced renal cell carcinoma). exclusion criteria: * patients not administered torisel. * patients with a history of severe hypersensitivity to temsirolimus, sirolimus derivative, or any of their components and/or derivatives.

Keywords: torisel regulatory post marketing commitment plan
effect of fish oil on adiposity and atherogenic factors in type 2 diabetic women

Conditions: Type 2 Diabetes

Summary: 1. whether the intake of n-3 pufa has additional effects on insulin sensitivity and adiposity (total fat mass and adipocyte morphology and function) in t2d women. 2. n-3 pufa supplementation might influence inflammatory genes expression in the adipose tissue of t2d patients.

thus, the present study was designed to evaluate the effects of n-3 pufas dietary supplementation on lipid and glucose homeostasis and to address the impact of this treatment on adiposity and adipose tissue gene expression in t2d women.a total of 27 t2d women (bmi 27-35kg/m², age 40-60 y) were randomly allocated to two months of 3 g/day of either fish oil (1.8 g n-3 pufa) or placebo (paraffin oil), in a double-blind parallel design.

Eligibility criteria:
inclusion criteria: 1. type 2 diabetic postmenopausal women 2. glycaemia of 7.87-14.0 mmol/l, hba1c of 7 to 10.5% 3. plasma triglycerides between 1.72-4.6 mmol/l, 4. aged between 40 -60, 5. bmi: 27-40 kg/m2 6. able to swallow tablets exclusion criteria: 1. patients with abnormal renal, hepatic and thyroid functions as determined by physical examination, blood cell count and standard blood biochemical profile 2. patients with gastrointestinal disorders 3. patients treated with thiazolidinediones or insulin

Keywords: fish oil type 2 diabetic women adiposity adipose tissue inflammation pai-1 insulin sensitivity
three daily wear monthly replacement silicone hydrogel contact lenses with two multi-purpose disinfecting solution combinations

Conditions: Refractive Errors

Summary: the purpose of this study is to evaluate corneal staining observed after 2 hours of wear with an investigational contact lens against both purevision contact lenses pre-cycled with biotrue and biofinity contact lenses pre-cycled with replenish.

subjects will be randomized in a 1:1:1:1 manner to receive one of 4 regimen sequences with lens and multipurpose disinfection solution (mpds) combinations. the expected duration of subject participation in the study is approximately 1 week with 2 study visit days.

Eligibility criteria:
key inclusion criteria: * understand and sign an informed consent; * successful wear of spherical soft contact lenses in both eyes for a minimum of 5 days per week and 8 hours per day during the past 3 months; * manifest cylinder of less than or equal to 1.50 diopter (d) in each eye; * best corrected visual acuity (bcva) better than or equal to 20/25 snellen in each eye; * willing to stop wearing habitual contact lenses for the duration of study lens exposure and during the washout period. * other protocol-specified inclusion criteria may apply. key exclusion criteria: * any eye condition or disease (including systemic) that contraindicates contact lens wear, as determined by the investigator; * any use of systemic or ocular medications for which contact lens wear could be contraindicated, as determined by the investigator; * eye surgery, as specified in the protocol; * dry eye; use of artificial tears, as specified in the protocol; * other protocol-specified exclusion criteria may apply.

Keywords: contact lens contact lens solution
double helix design defocus lens spectacle (race) for myopia control

Conditions: Myopia, Progressive

Summary: this study uses 1.585 double helix defocus lens pc lenses with a unique optical design that includes a globally coherent visible area and complementary left and right helices that can form clear images. in addition, the helical arrangement and reduced slit area can generate defocusing signals, inhibiting the development of myopia. therefore, based on previous research, this study plans to evaluate the safety and effectiveness of 1.585 double helix defocus lens pc frame eyeglasses in controlling the progression of myopia in children and adolescents through a randomized controlled clinical trial.


Eligibility criteria:
inclusion criteria: 1. race: chinese children and adolescents. 2. age 6-13 years, gender unrestricted. 3. cycloplegic refraction ser: -0.75ds\~-5.0ds in both eyes. 4. best corrected visual acuity of both eyes reaches 1.0 (0.00 logmar 6/6). 5. refractive astigmatism and astigmatism are no more than 1.5d. 6. during the study period, willing to wear glasses provided by the researcher only (\>10 hours) and without additional interventions. 7. willing to be randomly assigned. 8. able to sign an informed consent form with the accompaniment and understanding of parents or guardians. exclusion criteria: 1. allergic or intolerant to medications used for ciliary muscle paralysis. 2. received any nearsightedness treatment such as atropine, rigid gas permeable contact lens, bifocal/progressive lens, red light therapy, or acupuncture within 30 days before the study. 3. received defocus lenses for nearsightedness treatment in the past. 4. diagnosed with any eye disease other than nearsightedness, including strabismus (esotropia greater than 8 prism diopters or exotropia greater than 12 prism diopters), corneal diseases, conjunctival or eyelid damage or other conditions (such as keratoconus, herpes simplex keratitis, etc.). 5. history of eye surgery (including strabismus correction surgery). 6. eye or systemic diseases that might be associated with nearsightedness or its progression, such as marfan syndrome, retinopathy of prematurity, diabetes, etc. 7. anatomical or dermatological factors that may interfere with the wearing of spectacle frames. 8. other reasons that the researcher deems inappropriate for the participant to be included in the study, such as excessively high expectations for the effectiveness of defocus lenses, or plans to use other nearsightedness intervention strategies simultaneously with the study.
a study to assess the safety and effectiveness of prevenar in chinese children who have not previously received a vaccine against pneumococcal bacteria

Conditions: Pneumococcal Infections

Summary: a vaccine called prevenar is already approved for use in china for vaccination of children younger than 6 years old against infections caused by streptococcus pneumoniae. this study is to measure the amount of antibodies (antibodies help people fight off diseases) chinese children aged between 121 days and 6 years (72 months) produce when given prevenar. the study will also provide more data on how safe and well tolerated prevenar is in chinese children.


Eligibility criteria:
inclusion criteria: * healthy chinese male or female subjects. * between 121 days to less than 72 months of age at the time of entry into the study. exclusion criteria: * receipt of previous vaccine against pneumo * previous anaphylactic reaction to any vaccine or part of a vaccine * previous proven invasive pneumo infection * receipt of investigational drug or device within the proceeding 28 days

Keywords: prevenar catch-up pneumococcal pneumonia
platelet rich plasma versus corticosteroids in hip osteoarthritis pain

Conditions: Hip Osteoarthritis

Summary: prospective, single-center that may go on to being multicenter, randomized trial comparing platelet rich plasma (prp) versus corticosteroid injection for the treatment of symptoms of hip osteoarthritis. the purpose of the study is to determine which therapy provides a greater reduction in patient reported outcome measures of pain and function.

platelet rich plasma has become increasingly utilized as a treatment option for hip osteoarthritis. corticosteroids is currently an approved medication to treat the symptoms of the hip osteoarthritis. there is limited evidence in a prospective randomized manner powered adequately to determine a difference between these treatments for pain associated with hip osteoarthritis. prospective, single center that may go on to be multi-center, single blind (participant), randomized trial comparing platelet rich plasma (prp) versus corticosteroid injection for the treatment of symptoms of hip osteoarthritis. the purpose of the study is to determine which therapy provides a greater reduction in patient reported outcome measures of pain and function.

Eligibility criteria:
inclusion criteria: * provision of signed and dated informed consent form * stated willingness to comply with all study procedures and availability for the duration of the study * male or female, aged 21-80 years * radiographic diagnosis of kellgren-lawrence (kl) grade of ii or iii hip osteoarthritis * indicated for a hip injection to treat hip oa symptoms exclusion criteria: * any injections into the target hip within three months * current overlying skin infection * current or previous diagnosis of "chronic pain" * opioid tolerant at time of screening (for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid.) * allergy to any potential ingredients or medications utilized in any of the two groups * treatment with another investigational drug or other intervention for pain * diagnosis of diabetes mellitus * if female, pregnant or planning to be pregnant within the following 3 months or study duration * any condition(s) or diagnosis, both physical or psychological, or physical exam finding in the opinion of the investigator that would precludes participation

Keywords: platelet rich plasma hip osteoarthritis prp hip oa corticosteroids
artisential® for rectal cancer surgery

Conditions: Rectal Cancer

Summary: this study aimed to assess efficacy of artisential® in reducing laparoscopic rectal cancer surgery duration. we retrospectively reviewed the data of patients who underwent laparoscopic low or ultralow anterior resection for primary mid-to-low rectal cancer, performed by a single surgeon in 2012-2022. patients were divided into groups, use group vs. non-use group, based on the use or non-use of the artisential®. the total mesorectal excision quality and resection margin status did not differ between the groups. artisential® reduced operative time without impairing surgical quality or oncologic outcomes.


Eligibility criteria:
inclusion criteria: * mid-to-low rectal caner (witing 10cm of the anal verge) * laparoscopic surgery exclusion criteria: * combined surgery * recurrent rectal cancer surgery
long term safety assessment of ser120 in patients with nocturia

Conditions: Nocturia

Summary: the hypothesis of this study is that ser120 is safe and well tolerated for use in nocturic patients.


Eligibility criteria:
inclusion criteria: * patients completed spc-ser120-db1-200901 and spc-ser120-db2-200902 studies * willing to provide consent for the study exclusion criteria: * incontinence * diabetes insipidus, diabetes mellitus * chf * renal insufficiency * significant medical history which make participation unacceptable

Keywords: decrease in the number of nocturic episodes for patients with nocturia
botulinum toxin injection to treat diffuse esophageal spasm

Conditions: Esophageal Spasm, Diffuse

Summary: this study evaluates the effect of botulinum toxin 100 u or saline, injected endoscopically in the distal esophagus, on symptoms and manometry pattern in patients with diffuse esophageal spasm.

patients are selected on the basis of a clinical diagnosis of diffuse esophageal spasm, based on endoscopy and manometry. this is a sham-controlled cross-over study of injection of botulinum toxin or saline, in randomized order, in the distal esophagus. all patients have undergone esophageal manometry which shows diffuse esophageal spasm, and a 24h ph monitoring/manometry to quantify acid reflux. all drugs prescribed to affect esophageal motility (nitrates, calcium antagonists) are stopped during the study. after randomisation, the patient will undergo standard esophageal manometry to assess baseline esophageal motility. on the same day the patient will be asked to fill out a set of symptom questionnaires including a dysphagia questionnaire. at endoscopy, the active treatment group receives 8 x 12.5 units, each in 0.5 ml, of botulinum toxin a which will be injected in the four quadrants of the esophagus at 2 and 5 cm above the lower esophageal sphincter. in the sham group 8 \* 0.5 ml of physiologic serum will be injected. the randomisation will be performed at the endoscopy unit by a nurse otherwise not involved in the protocol. after 1 month a stationary manometry and a new esophageal ph/manometry monitoring will be performed, followed by a second endoscopy with injection of saline or botulinum toxin in a cross-over mode. at the time of the second endoscopy each patient will fill out a dysphagia questionnaire. one month later, the dysphagia questionnaire is repeated. subsequently, follow-up will occur at the outpatient clinic after 6 and 12 months, with follow-up dysphagia questionnaires but no additional manometries or endoscopies, unless the clinical status deteriorates.

Eligibility criteria:
inclusion criteria: * spastic motor disorder in the upper gi tract exclusion criteria: -

Keywords: weight loss dysphagia esophageal hypermotility chest pain
effect of prp joint cavity combined with acupoint injection on osteoarthritis of knee joint

Conditions: Early Knee Osseous Arthrophlogosis

Summary: this study collected general data from 90 patients with koa in the outpatients and ward of henan provincial people's hospital from january 2023 to december 2023 to compare the long-term effects of intra-articular prp combined with acupoint prp, intra-articular prp, and intra-articular ha on symptoms in patients with mild to moderate osteoarthritis


Eligibility criteria:
inclusion criteria: 1. the expected survival period is more than 3 months; 2. the clinical diagnosis was early knee osteoarthritis; 3. capable of knee injections; 4. chronic joint pain or swelling (\> 4 months); 5. it meets the diagnostic criteria of the chinese guidelines for the diagnosis and treatment of osteoarthritis (2021 edition) , and the x-ray evaluation results meet the kellgren-lawrence scale (k-l scale) level i to level iii. exclusion criteria: 1. age over 80 years old; 2. k-l classification is greater than ⅲ grade; 3. combined with rheumatoid arthritis, severe osteoporosis, tumor, gout, obvious joint deformity and other diseases; 4. poor compliance, not according to the provisions of treatment; 5. pregnant and lactating women; 6. patients voluntarily withdrew from the study; 7. patients were lost to follow-up due to various reasons during follow-up.
the efficacy and mechanism of sma+m1 repetitive transcranial magnetic stimulation on freezing of gait in pd

Conditions: Parkinson Disease

Summary: this study is a double-blinded randomized study examining the efficacy of the double-site (m1+sma) repetitive transcranial magnetic stimulation on freezing of gait (fog) in patients with parkinson's disease. the investigators hypothesize that treatment using magnetic stimulation on double site (including m1-ll and sma) will improve fog and gait symptoms in patients with parkinson's disease.

patients in the double-site group underwent ten sessions of double-site high frequency rtms over the bilateral primary motor cortex of the lower leg and supplementary motor area, whereas patients in the single-site group underwent ten sessions of single-site active magnetic stimulation with high frequency rtms over the bilateral primary motor cortex of the lower leg. in addition, patients in the sham group underwent 10 sessions of sham rtms on bilateral primary motor cortex of the lower leg. assessments of fog severity, gait, motor symptoms, excitability of cortex motor (using transcranial magnetic stimulation), plasma indicators and multimodal magnetic resonance were performed three times: at baseline, one day post intervention, one month post intervention.

Eligibility criteria:
inclusion criteria: 1. aged between 40-80 years; 2. diagnosis of idiopathic parkinson's disease (pd) according to the movement disorder society clinical diagnostic criteria; 3. patients were stable on dopaminergic treatment for at least 3 months; 4. item 3 of the freezing of gait questionnaire(fog-q) scored ≥1; 5. patients experienced fog during an interview. exclusion criteria: 1. comorbidities of major neurologic diseases other than pd; 2. suffer from musculoskeletal disorders that could have interfered with their ability to walk; 3. presence of contraindications for transcranial magnetic stimulation (tms) and magnetic resonance imaging (mri); 4. marked tremor interfered with tms detection; 5. previously receiving any kinds of tms interventions; 6. severe cognitive impairment making cooperation impossible \[mini mental state examination (mmse) \< 24\]; 7. were unable to walk independently during the off state.

Keywords: parkinson's disease gait symptoms freezing of gait tms neural mechanism
comparison of the effect of helicobacter pylori eradication before and after the training of gastroenterologists

Conditions: Helicobacter Pylori Infection

Summary: the researchers recruited gastroenterologists. physician subjects recruited helicobacter pylori-positive patients before and after receiving standardized training on helicobacter pylori eradication. there are no restrictions on treatment options and drugs during the trial. compare the eradication rate, adverse reaction rate, and patient compliance before and after physician training.

the researchers recruited gastroenterologists to participate in the study, and gastroenterologists recruited helicobacter pylori-positive patients. in this process, the patient population is not limited, and the eradication program is not limited. gastroenterologists can follow up or not follow up according to their original diagnosis and treatment. researchers follow up and record the patient's medication status and adverse reactions in the medication process by phone or wechat, and evaluate patient compliance. record the eradication rate. after waiting for all patients admitted by gastroenterologists to be eradicated and re-examined, we will provide standardized helicobacter pylori eradication training for gastroenterologist subjects. after the training, gastroenterologists recruit helicobacter pylori-positive patients here. in this process, the patient population is not limited, and the eradication program is not limited. gastroenterologists can follow up or not follow up according to their original diagnosis and treatment. researchers follow up and record the patient's medication status and adverse reactions in the medication process by phone or wechat, and evaluate patient compliance. record the eradication rate. compare the eradication rate, the incidence of adverse reactions, and the compliance of the patients before and after the training of the gastroenterologists.

Eligibility criteria:
inclusion criteria: * 1.physician specialized in gastroenterology. * 2.diagnosis and treatment conditions for h. pylori exist in the hospital where the gastroenterology doctor is located. (c13 urea breath test, c14 urea breath test, rapid urease test, stool h. pylori antigen test, histopathological test, h. pylori culture, any of the above) exclusion criteria: * 1.those who are unable or unwilling to provide informed consent. * 2.patients with h. pylori have never been diagnosed and treated.

Keywords: standardized training on helicobacter pylori eradication gastroenterologist